Reaction
Oropharyngeal Blistering reporting signals
As of the last recalculation, Oropharyngeal Blistering appears in 1,624 FAERS reports alongside 18 co-occurring drug terms. The strongest observed disproportionality signal is ASENAPINE MALEATE (PRR 33.0).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Asenapine Maleate | 22 | 33.0 | 33.1 |
| Nicotine Polacrilex | 48 | 16.5 | 16.6 |
| Varenicline Tartrate | 84 | 14.1 | 14.1 |
| Sorafenib | 22 | 13.7 | 13.8 |
| Armodafinil | 19 | 11.7 | 11.7 |
| Sunitinib Malate | 22 | 7.3 | 7.3 |
| Regorafenib | 6 | 6.6 | 6.6 |
| Nicotine | 19 | 6.1 | 6.1 |
| Vemurafenib | 5 | 5.3 | 5.3 |
| Romiplostim | 6 | 5.1 | 5.1 |
| Peginterferon Alfa-2A | 21 | 5.0 | 5.0 |
| Lapatinib | 6 | 5.0 | 5.0 |
| Budesonide, Glycopyrrolate, And Formoterol Fumarate | 4 | 4.9 | 4.9 |
| Cabozantinib | 16 | 4.3 | 4.3 |
| Orlistat | 8 | 4.0 | 4.0 |
| Nirmatrelvir And Ritonavir | 11 | 2.6 | 2.6 |
| Palivizumab | 3 | 2.5 | 2.5 |
| Bimekizumab | 4 | 2.4 | 2.4 |